Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,079,816
  • Shares Outstanding, K 201,440
  • Annual Sales, $ 12,274 M
  • Annual Income, $ 2,539 M
  • 36-Month Beta 0.89
  • Price/Sales 5.63
  • Price/Cash Flow 12.67
  • Price/Book 5.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 6.80
  • Number of Estimates 26
  • High Estimate 7.23
  • Low Estimate 6.49
  • Prior Year 6.31
  • Growth Rate Est. (year over year) +7.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
330.89 +4.33%
on 07/31/18
388.67 -11.18%
on 07/25/18
-9.76 (-2.75%)
since 07/17/18
3-Month
276.42 +24.89%
on 05/21/18
388.67 -11.18%
on 07/25/18
+64.65 (+23.04%)
since 05/17/18
52-Week
249.17 +38.55%
on 04/24/18
388.67 -11.18%
on 07/25/18
+60.80 (+21.38%)
since 08/17/17

Most Recent Stories

More News
Lilly (LLY) Hits 52-Week High, Can the Run Continue?

Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

LLY : 105.55 (+1.14%)
VRTX : 176.08 (+0.64%)
BMY : 60.89 (-0.36%)
BIIB : 345.22 (+0.67%)
Is Biogen (BIIB) Outperforming Other Medical Stocks This Year?

Is (BIIB) Outperforming Other Medical Stocks This Year?

BIIB : 345.22 (+0.67%)
Has Biogen (BIIB) Outpaced Other Medical Stocks This Year?

Is (BIIB) Outperforming Other Medical Stocks This Year?

BIIB : 345.22 (+0.67%)
Pain Therapeutics' Shares Rally on Alzheimer's Study Grant

Pain Therapeutics (PTIE) receives grant of $3.2 million from National Institutes of Health to support development of its Alzheimer's disease candidate, PTI-125.

PTIE : 0.92 (-10.68%)
MRK : 69.06 (+0.31%)
RHHBY : 30.1200 (+0.57%)
BIIB : 345.22 (+0.67%)
Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children

Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years

LGND : 247.98 (+3.47%)
VRTX : 176.08 (+0.64%)
GILD : 72.92 (-3.53%)
BIIB : 345.22 (+0.67%)
SmarTrend Watching for Potential Rebound in Shares of Biogen Inc After 1.20% Loss

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $338.37 to a high of $343.92. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $339.22...

BIIB : 345.22 (+0.67%)
Biotech ETFs in Focus on String of Q2 Earnings Beat

Biotech ETFs draw attention post impressive Q2 results.

IBB : 116.29 (+0.02%)
FBT : 149.76 (+0.05%)
BBH : 129.40 (-0.01%)
IEIH : 26.23 (-0.46%)
GILD : 72.92 (-3.53%)
AMGN : 197.42 (+0.50%)
ALXN : 116.00 (-1.09%)
BIIB : 345.22 (+0.67%)
Biotech ETFs in Focus on String of Q2 Earnings Beat

Biotech ETFs draw attention post impressive Q2 results.

IBB : 116.29 (+0.02%)
FBT : 149.76 (+0.05%)
BBH : 129.40 (-0.01%)
IEIH : 26.23 (-0.46%)
GILD : 72.92 (-3.53%)
AMGN : 197.42 (+0.50%)
ALXN : 116.00 (-1.09%)
BIIB : 345.22 (+0.67%)
PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y

PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.

PDLI : 2.33 (unch)
ILMN : 325.88 (-0.34%)
GILD : 72.92 (-3.53%)
BIIB : 345.22 (+0.67%)
Recommended Cash Offer for Vernalis plc

LNSTY : 14.3700 (+1.63%)
MRK : 69.06 (+0.31%)
BK : 51.69 (+0.33%)
BAX : 72.04 (+0.64%)
NVS : 83.04 (+1.03%)
VNLPF : 0.2190 (unch)
AMGN : 197.42 (+0.50%)
BIIB : 345.22 (+0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 351.43
1st Resistance Point 348.32
Last Price 345.22
1st Support Level 340.62
2nd Support Level 336.03

See More

52-Week High 388.67
Last Price 345.22
Fibonacci 61.8% 335.38
Fibonacci 50% 318.92
Fibonacci 38.2% 302.46
52-Week Low 249.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar